<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518855</url>
  </required_header>
  <id_info>
    <org_study_id>11518</org_study_id>
    <nct_id>NCT01518855</nct_id>
  </id_info>
  <brief_title>Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension</brief_title>
  <official_title>Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate incremental cost effectiveness of
      Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of
      essential hypertensive patients.

      To investigate incremental cost effectiveness, primary variables are mean treatment cost and
      achievement rate to target blood pressure level at the end of double-blind treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean treatment cost* for 16-week of double-blind treatment period</measure>
    <time_frame>16 weeks</time_frame>
    <description>* Including treatment cost for the drug related AEs. The sponsor will calculate the cost based on the tariff of health insurance scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants** achieving target blood pressure at the end of double-blind treatment period</measure>
    <time_frame>at week 16</time_frame>
    <description>**For subjects aged under 60 years: SBP&lt;130mmHg and DBP&lt;85mmHg, for subjects aged 60 years or over: SBP&lt;140mmHg and DBP&lt;90mmHg (SBP Systolic blood pressure, DBP Diastolic blood pressure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment cost per subject to achieve the target blood pressure (Total costs for the double-blind treatment period / Number of patients who achieve the target blood pressure at the end of double-blind treatment period)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in blood pressure (SBP and DBP) from the baseline (end of pretreatment period) .</measure>
    <time_frame>baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants for each age group to target blood pressure level</measure>
    <time_frame>at week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent drug-related adverse events</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables will be summarized using descriptive statistics based on adverse events collections</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalat CR 20-40mg od + Diovan 40-80mg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norvasc 2.5-5mg od + Diovan 40-80mg od</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat, BAYA1040)</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine (Norvasc)</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diovan</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Untreated patients or patients with previous treatment by antihypertensive agents whose
        blood pressure at sitting position at the time of the entry (Visit 1) is:

          -  SBP&gt;/=160mmHg or DBP&gt;/=100mmHg for untreated patients (SBP Systolic blood pressure,
             DBP Diastolic blood pressure)

          -  SBP&gt;/=150mmHg or DBP&gt;/=95mmHg for patients with previous treatment by antihypertensive
             agents

        Exclusion Criteria:

          -  Patients whose blood pressure on either day of Visit 1 or 2 is: SBP &gt; 200mmHg or DBP &gt;
             120mmHg.

          -  Patients with secondary hypertension or hypertensive emergency such as malignant
             hypertension.

          -  Patients with a history of cardiovascular or cerebrovascular ischemic event (stroke,
             transient ischemic attack, myocardial infarction or unstable angina) within six months
             prior to the study.

          -  Patients with a history of intracranial or subarachnoid hemorrhage within six months
             prior to the study.

          -  Patients with uncontrolled diabetes (HbA1c &gt;/=8%)

          -  Patients with bradycardia or tachycardia (&lt;50 bpm, &gt;/=100 bpm), arrhythmia such as
             atrioventricular block (second and third degree), sinoatrial block or atrial
             fibrillation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>163-6003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>733-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Head Medical Development Japan</name_title>
    <organization>Bayer Yakuhin Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

